OM
CRNX icon

Opaleye Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Opaleye Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-210,000
Closed -$9.83M – 54
2024
Q1 		$9.83M Sell
210,000
-97,500
-32% -$3.81M 2.14% 16
2023
Q4 		$10.9M Sell
307,500
-62,500
-17% -$1.92M 2.91% 10
2023
Q3 		$11M Sell
370,000
-475,000
-56% -$9.79M 3.58% 9
2023
Q2 		$15.2M Buy
845,000
+59,206
+8% +$1.18M 3.64% 5
2023
Q1 		$12.6M Buy
785,794
+53,794
+7% +$996K 3.78% 5
2022
Q4 		$13.4M Buy
732,000
+60,700
+9% +$1.07M 4.66% 5
2022
Q3 		$13.2M Hold
671,300
– – 5.45% 5
2022
Q2 		$12.5M Sell
671,300
-21,700
-3% -$433K 5.64% 4
2022
Q1 		$15.2M Sell
693,000
-31,400
-4% -$636K 4.72% 5
2021
Q4 		$20.6M Buy
724,400
+322,287
+80% +$7.95M 4.36% 7
2021
Q3 		$8.46M Buy
402,113
+201,613
+101% +$4.22M 1.58% 21
2021
Q2 		$3.78M Buy
200,500
+12,500
+7% +$220K 0.63% 39
2021
Q1 		$2.87M Buy
+188,000
New +$2.91M 0.42% 47
2020
Q4 		– Sell
-240,000
Closed -$3.76M – 61
2020
Q3 		$3.76M Sell
240,000
-195,200
-45% -$2.98M 0.74% 36
2020
Q2 		$7.63M Buy
435,200
+66,450
+18% +$1.13M 1.54% 24
2020
Q1 		$5.42M Buy
368,750
+102,650
+39% +$2.1M 1.44% 21
2019
Q4 		$6.68M Buy
266,100
+59,100
+29% +$1.13M 1.31% 33
2019
Q3 		$3.11M Buy
207,000
+171,000
+475% +$3.33M 1.13% 32
2019
Q2 		$900K Sell
36,000
-37,000
-51% -$916K 0.27% 40
2019
Q1 		$1.66M Buy
+73,000
New +$1.79M 0.46% 46

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Opaleye Management's CRNX Position: Q2 2024 in Review

Opaleye Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2024, closing a stake of 210,000 shares — an estimated $9.83M sold.

Opaleye Management first reported a position in CRNX in Q1 2019 and held it in 20 quarters. The position peaked at $20.6M in Q4 2021. 234 funds tracked by Wall St. Rank hold CRNX as of Q2 2024.

  • Opaleye Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Opaleye Management sold 210,000 Crinetics Pharmaceuticals shares in Q2 2024, an estimated $9.83M.
  • Opaleye Management first reported a position in Crinetics Pharmaceuticals in Q1 2019 and held it in 20 quarters.
  • Opaleye Management's Crinetics Pharmaceuticals position peaked at $20.6M in Q4 2021.
  • 234 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2024.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.